Use of cyclic enol ether terpenoid for producing promotive neurocyte proliferate and differentiation medicament

A technology for nerve cell proliferation and iridoids, which is applied in the field of treatment or prevention of diseases or disorders related to the promotion of nerve cell proliferation and/or differentiation, and can solve problems such as loss of stimulating effect of active factors

Active Publication Date: 2008-09-03
XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI
View PDF1 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, a large number of in vitro and in vivo experiments have confirmed that NSCs ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cyclic enol ether terpenoid for producing promotive neurocyte proliferate and differentiation medicament
  • Use of cyclic enol ether terpenoid for producing promotive neurocyte proliferate and differentiation medicament
  • Use of cyclic enol ether terpenoid for producing promotive neurocyte proliferate and differentiation medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Loganin and Morroniside Promote the Survival and Proliferation of Neural Stem Cells

[0067] 1. Purpose of the experiment

[0068] To observe the effects of loganin and morroniside on the survival and proliferation of neural stem cells.

[0069] 2. Experimental method

[0070] Take a newborn SD rat one day old, take out the brain under aseptic conditions, separate the hippocampus, and place it in a petri dish filled with a small amount of high-glucose DMEM / F12; peel off the meninges and vascular tissues, cut the tissues as much as possible, and add cells for culture Gently pipet with a flame-polished Pasteur pipette to make a cell suspension, filter through a 400-mesh sieve, and count the proportion of viable cells by staining with placenta blue. 6 Cells / ml were inoculated into 25ml culture flasks. Using basal culture medium DMEM / F12 (1:1) and B27 (2%), and adding loganin and morroniside at final concentrations of 10, 50, 100, 200, 400 μg / ml respectively, the culture...

Embodiment 2

[0075] Effects of loganin and morroniside on promoting the differentiation of neural stem cells

[0076] 1. Purpose of the experiment

[0077] Observing the effects of loganin and morroniside on the differentiation of neural stem cells

[0078] 2. Experimental method

[0079] The second-generation neural stem cell spheres were taken, and the culture medium containing growth factors in the culture bottle was removed, and the cell spheres were randomly divided into two groups, ① fetal bovine serum (FBS) control group: the culture medium was DMEM / F12+10% FBS; ② Drug treatment group: Add loganin or morroniside at final concentrations of 10, 50, and 100 μg / ml to FBS-free culture medium DMEM / F12, respectively, and the above two groups of cells are cultured in 24 wells covered with polylysine In the plate, immunofluorescent staining was performed 7 days later, and observation and photography were taken.

[0080] 3. Experimental results

[0081] In the fetal bovine serum control g...

Embodiment 3

[0084] The combination of loganin and morroniside promotes the proliferation of neural stem cells after brain injury

[0085] 1. Purpose of the experiment

[0086] Observation of the effect of loganin and morroniside composition on neurogenesis in stroke rat model

[0087] 2. Experimental method

[0088] SD rats were intragastrically given a composition of loganin and morroniside (1:1) (180 mg / kg in a large dose, 60 mg / kg in a medium dose, and 20 mg / kg in a small dose). For the rat model of cerebral ischemia, Brdu (10 mg / ml, 50 mg / kg / time, 2 times / d) was given intraperitoneal injection within 4 to 7 days after model establishment to label endogenously proliferating cells, perfused on the 8th day, fixed, The brains were taken out and serially frozen sections with a thickness of 30-40um were subjected to immunofluorescent staining.

[0089] 3. Experimental results

[0090] There are scattered Brdu-positive cells in the dentate gyrus (DG) and subventricular zone (SVZ) of the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of iridoids in preparing drugs for promoting nerve cell proliferation and/or differentiation and a method for treating diseases related to nerve cell proliferation and/or differentiation by using the same.

Description

technical field [0001] The invention relates to the use of iridoid compounds in the preparation of drugs for promoting the proliferation and / or differentiation of nerve cells and the prepared pharmaceutical composition. The present invention also relates to methods of treating or preventing diseases or conditions associated with promoting neural cell proliferation and / or differentiation with said compounds or pharmaceutical compositions. technical background [0002] Neural stem cells (NSCs) refer to pluripotent cells in the central nervous system that have self-renewal ability and can differentiate into mature brain cells (including neurons, astrocytes and oligodendrocytes). Neural stem cells have self-renewal ability, high proliferation potential and multi-differentiation potential, and can be differentiated into neurons, oligodendrocytes and astrocytes, etc. The progeny cells produced by neural stem cells play an important role in the development, maintenance and Impleme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/351A61K31/352A61P25/28A61P21/04
CPCA61K31/7048A61P9/10A61P21/04A61P25/00A61P25/16A61P25/28
Inventor 李林王文魏海峰姚瑞芹李小黎张如意
Owner XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap